Zydus Lifesciences receives USFDA EIR for Jarod injectable facility
Zydus Lifesciences has received an Establishment Inspection Report (EIR) from the USFDA for its Jarod injectable manufacturing plant, confirming the successful closure of the inspection and strengthening the company’s regulatory position in sterile injectables
By Finblage Editorial Desk
12:45 pm
4 December 2025
Sources & Disclaimer
This article is compiled from publicly available information, including company disclosures, stock exchange filings, regulatory announcements, and reports from global and domestic financial publications. The content has been editorially reviewed and enhanced by the Finblage Editorial Desk for clarity and investor awareness purposes only.
All information provided on Finblage is strictly for educational and informational use and should not be considered as financial, investment, legal, or professional advice. Readers are advised to conduct their own independent research and consult a certified financial advisor before making any investment decisions. Finblage shall not be held responsible for any losses arising from the use of information published on this website.
_edited.png)





